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ABSTRACT
The study aimed to assess the capacity of AEFI surveillance during vaccination campaigns with the new
conjugate meningitis vaccine (MenAfrivac). A systematic review of studies on MenAfrivac™ published in
English during 2001–2016 was done.AEFIs incidence (I) was estimated and compared between
MenAfrivac™ clinical trials and immunization campaigns using incidence difference (Id). Nine studies
were included with an overall local AEFI I of 11,496/100,000 doses administered per week in clinical trials
and 0.72/100,000 doses in immunization campaigns. An Id of 11,497.92 [11,497.91-11,497.93] and
17,243.20 [17,241.80-17,245.90] per 100,000 doses administered per week for overall local and systemic
AEFI, respectively, were observed with highest from clinical trials. The incidence of AEFIs after
MenAfrivac™ vaccination was far lower in campaigns than in clinical trial studies. Current capacity of
AEFI surveillance during vaccination campaigns requires extensive re-assessment of its structure and
capacity.
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1. Introduction
1.1 Background
In clinical trials, the monitoring of vaccines and drugs safety is
mandatory and harmonized. Phase I clinical trials have as main
objective to assess vaccine safety but the number of participants
is usually limited and consequently, do not allow the detection of
rare adverse events.1 Unlike the marketed phase of vaccines,
gradually increasing sample size of participants in phases 2, 3,
and 4 clinical trials remains insufficient to detect rare adverse
events following immunization (AEFIs).2
AEFIs surveillance after post-licensure is expected to improve
vaccines safety by detecting and investigating as well as preventing
the following; vaccine quality defect-related reaction, immuniza-
tion error-related reaction, immunization anxiety-related reac-
tion; to estimate vaccine reaction rates (background rates) in the
population and to ensure and facilitate causality assessment of
coincidental, serious and unexpected/unusual AEFIs.1,3–5 It pro-
vides useful information to anticipate or respond to public con-
cerns about the safety of vaccines and thus contributes to increase
the adherence of the public to vaccination.5,6 The currently
published studies indicate that AEFIs surveillance is below expec-
tations due to weaknesses such as low detection rates, reporting
rates and investigation of AEs.7–10 Comparing the geographical
distribution of AEFI surveillance data provided useful informa-
tion to monitor vaccines safety while mapping some weaknesses
of AEFIs surveillance systems.11 An estimation of the magnitude
of the difference in incidence and type of AEFI collected during
clinical development phases of vaccine and post-marketing sur-
veillance; could be useful to evaluate the amount of AEs not
reported by either vaccinees themselves or health personnel dur-
ing campaigns or routine immunization.
The PSA-TT vaccine (MenAfrivac™) was developed to
respond to meningococcal meningitis A outbreaks raging in
more than 21 African countries.12 MenAfrivac clinical trials
demonstrated the vaccine to be safe and effective thus, the vac-
cine was licensed in India in 2009 and pre-qualified by WHO
a year later.12–15 From the introduction of the vaccine in Burkina
Faso in 2010 to 2012, 10 African countries have been targeted by
vaccination campaigns, with a total of 100 million individuals
vaccinated.12 AEFI surveillance has been an important part of
these campaigns with results published in three countries.16–19
Although the number of people vaccinated gradually
increases from phase 1 to phases 4 clinical trials and to
vaccination campaigns, there is a decrease in AEFIs incidence
during vaccination campaigns due to reduced capacity of
AEFIs surveillance. There is a public health advantage during
mass campaigns as the immunized population during mass
campaign does not only have a high sample size power but,
the population is also diversified and therefore has the ten-
dency to allow the detection of rare serious AEFI that may
only occur in specific populations. These rare events are not
expected to be captured during clinical trials because clinical
trials do not have sufficient power to assess such rare AEFIs.
Moreover, conditions of storage and use of vaccines are less
likely to be complied with during mass campaigns and thus,
CONTACT Ayok M. Tembei maureentembei@gmail.com P.O. BOX 33490, Yaoundé, Cameroon
HUMAN VACCINES & IMMUNOTHERAPEUTICS
2020, VOL. 16, NO. 6, 1245–1259
https://doi.org/10.1080/21645515.2019.1652041
© 2019 Taylor & Francis Group, LLC
predisposing to a potential increase of AEFIs incidence. With
an aim to inform AEFIs surveillance activities for better
planning and monitoring of MenAfrivac™ campaigns, this
study compared the incidence and distribution of AEFIs
reported during clinical trial phases to that reported during
immunization campaigns.
2. Results
2.1. Study selection
ByMarch 17, 2015, the search identified 128 titles which included
53 (43.1%) from the Meningitis Vaccine Project (MVP) website,
63 (47.2%) fromMedline, 10 (8.1%) fromOvid and 2 (1.6%) from
references of articles. After eliminating duplicates, a total 114 titles
and abstracts were further screened of which 13 full texts were
selected and 9 included in the study. Four could not provide
needed data to estimate AEFIs incidence and thus, were
excluded.20–23
Figure 1 illustrates the selection process.
2.2. Study characteristics
Table 1 presents characteristics of included articles. Three articles
which include four studies reported clinical trials;13–15 three
articles reported three studies on AEFI surveillance during immu-
nization campaigns and one article reported a phase 4 field trial
assessing MenAfrivacTM safety when delivered in a controlled
temperature chain.17,18,22,25 With respect to geographical factors,
two studies (clinical trials) were conducted in the Asian region
precisely in Indiawhile the remaining six studies (two clinical trials
and four vaccination campaigns) were conducted in the African
region representing Mali, Gambia, Senegal, Niger, Burkina Faso,
Benin, and Cameroon. For clinical trials, different age groups of
participants ranging from 1 to 35 years were included in all of the
four trial studies while for mass campaign studies, the same age
group (1–29 years) of participants were included. Also, the num-
ber of persons vaccinated varied within clinical trials (with
a minimum number of 24 and a maximum of 604) and mass
campaign studies (minimum of 1999 and maximum of
11,117,555). All included studies had the same number of doses
administered (0.5ml) be it clinical trial ormass campaign and also,
the same number of doses administered per person except for one
clinical study, which administered a primary dose and a booster
dose. All vaccines administered to participants both for trials and
campaigns were manufactured by the same manufacturer (Serum
Institute India Ltd).
Table 2 presents characteristics of AEFIs surveillance among
included studies. All included studies employed active surveil-
lance except for one campaign study that used passive
Figure 1. Flow diagram illustrating the selection process.
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surveillance method for case detection. Two campaign studies
used a combination of both active and passive surveillance
methods. All clinical trial studies and one campaign study did
not include case definitions for minor and serious AEFI while
the remaining three campaign studies included case definition of
AEFI which complied with the WHO case definition. The prob-
ability of detecting AEFI for all vaccinated persons was the same
in clinical studies but not the same for three mass campaign
studies. AEFI case reporting procedure was the same for all
studies that had description of the reporting procedure. All
included studies investigated serious AEs. The surveillance
time for active follow-up varied across studies ranging from 4
to 7 days after vaccination.
2.3 Incidence of AEFI in clinical trials and in
immunization campaign studies
In total, 13,919,052 doses of MenAfrivacTM comprising 1190
from clinical trials and 13,917,862 from immunization cam-
paigns were reported to have been administered following
manufacturer’s recommendations from articles included in
this study. IR of overall AEFI in clinical trials and immuniza-
tion campaign studies are presented in Table 3. IR of AEFIs
were lower in immunization campaign studies than in clinical
trials. The AEFI IRs of clinical trials, mass immunization
campaigns and overall were 10,046.9, 4.5 and 3.7 per
100,000 doses administered per week, respectively.
2.3.1 AEFI incidence in clinical trials
Most clinical trials recorded details on the type of AEFIs only
for 4–7 days of surveillance; and therefore, only this period
was considered in estimating IR of AEs per type and char-
acteristics (local or systemic) in clinical trial studies. Table 4
presents AEFI IR in clinical trial studies. The IR per 100,000
doses administered per week, for local and systemic AEFIs
were 11,499, and 17,248, respectively. Among local AEFIs, the
highest IR was reported for pain at injection site while the
highest among systematic AEFIs was headache.
2.3.2 AEFI incidence in mass vaccination campaigns
Table 5 presents IRs of AEFIs reported in studies on vaccina-
tion campaigns. The IR per 100,000 doses administered per
week of local and systemic AEFIs were 0.72 and 2.63, respec-
tively, for immunization campaigns. The highest IR reported
among local reactions was a pain at the injection site and fever
among systematic reactions.
2.3.3 Serious AEFI in clinical trials and vaccination
campaign studies
A total of 51 severe AEFI were reported including 10 (1.56
serious AEFIs per 100,000 doses administered per week) from
clinical trials and 41 (0.08 serious AEFIs per 100,000 doses
administered per week) from mass vaccination campaign stu-
dies. Tables 6 and 7 present types and etiologies of severe
AEFIs in clinical trials and vaccination campaigns, respec-
tively. Types of AEFI reported in clinical trial studies differed
to that reported during vaccination campaign studies. After
causality assessment of all cases reporting with severe AEFI,
none of the serious AEFIs reported during clinical trials was
related to the vaccine. Causality assessment was conducted for
40 out of 41 reported serious AEFIs in vaccination campaign
studies and 5 were probably related to vaccine (12.5%) while 5
(10%) were not classified because of lack of information.
2.4. Comparing AEFI incidence rate in clinical trials and
vaccination campaign studies
The IRds of local, systemic, types and serious AEFI are pre-
sented in Table 8. IR of AEFIs were lower in immunization
campaign studies than in clinical trials, with the difference
(IRd) for overall AEFIs being 10,043 (95% CI 10,042–10,044)
per 100,000 doses per week, for local being 11,498 (95% CI
11,498–11,498), for systemic being 17,243 (95% CI 17,242–-
17,246) and for serious AEFIs being 1.55 (95% CI 1.54–1.56).
In some studies, some types of AEFIs were aggregated and
thus, the IRd of these AEFI were not presented in this study.
Headache had the highest IRd [3,622 (95% CI 3,622–3,623)]
Table 3. Incidence rate (IR) of overall reported studies in clinical and campaign studies.
Study
Vaccine development
phase
Number of
AEFIs
reported
Number of
doses
administered
Duration of AEFIS
surveillance in days
Duration of
surveillance in
persons week
IR(number of AEFI per 100ʹ000
doses administered per week)
Kshirsagar 200713 Phase 1clinical trial 27 24 7 24 112,500.0
Sow 2011(A)14 Phase 2clinical trial 179 393 28 1,572 11,387.0
Sow 2011(B)14 Phase 2-3clinical trial 110 604 28 2,416 4,553.0
Hirve: 201215 Phase 2-3clinical trial 155 169 28 676 22,929.0
Total clinical trials 471 1,190 4,688 10,046.9
Maman201217 Phase 2-3clinical trial 175 356,532 42 2,139,192 8.2
Ouandaogo 201218 Post registration
(immunization
campaign)
2,008 11,466,950 42 68,801,700 2.9
Steffen 201425 Post registration
(immunization
campaign)
439 999 5 713.57 61,521.6
Ateudjieu 2016 Post registration
(immunization
campaign)
1,124 2,093,381 42 12,560,286 8.9
Total campaign
studies
Post registration
(Phase 4)
3,746 13,917,862 83,501,892 4.5
Overall clinical trials
and campaign
studies
4,217 13,919,052 83,506,580 5.1
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among systemic reactions while pain at injection site had the
highest IRd 5,118.90 [95% CI 5,118.86–5,118.94] among local
reactions. An attributable fraction of AEFIs IR was more than
99% for overall, local and systemic AEFIs and also for serious
AEFIs in clinical trials than immunization campaigns.
2.5. Risk of bias within studies
Two review authors independently assessed the risk of bias of
each included study against key criteria such as random
sequence generation, allocation concealment, surveillance
time and minor and serious AEFI case definitions, incomplete
outcome data and participant follow-up procedures and selec-
tive reporting, in accordance with methods recommended by
the Cochrane Collaboration.24 Authors resolved disagree-
ments by consensus and a third author was consulted to
resolve disagreements if necessary.
Table 9 presents the assessment of the risk of bias in
included studies. Assessment of the risk of selection bias
was limited due to the fact that information on participants’
selection in clinical trial studies was not sufficiently detailed.
Case definitions of minor and serious AEFIs were not pre-
sented for all clinical trials thus, limiting the assessment of
detection bias. There existed an increased risk of detection
bias across studies because the duration and detection pro-
cedures of AEFI surveillance and of serious AEFI surveil-
lance were different in all included studies. Risk of detection
bias also existed among studies conducted during immuniza-
tion campaigns as all vaccinated populations had varying
geographic access to AEFI surveillance. In some of the
included studies, AEFI was only presented in syndrome or
in systemic organ class without prior presentation of symp-
tom or sign. This predisposed to an increased risk of
reporting bias in and across studies. There existed limited
information to rule out the risk of attrition bias for 6 out of
7 included studies as nothing was mentioned on followed-up
procedures for each study participants till the end of the
surveillance period. The causality assessment of serious
AEFIs was not clearly described in clinical trial studies
meanwhile campaign studies, it was conducted by
a multidisciplinary committee. This could increase the risk
of bias across studies regarding the classification of serious
AEFIs.
3. Discussion
To the best of our knowledge, this is the first systematic
review comparing incidence rates of AEFIs between clinical
trial phases and immunization campaigns with MenafrivacTM,
but also with any other vaccines. From prior experience, it
was known/expected for AEFI during mass campaigns to be
inadequate in comparison to clinical trials, but the level of
incompetency was alarming. This study, therefore, provides
an insight into the magnitude of difference in incidence rates
of overall, local, systemic, serious and types of AEFI when
assessed in a controlled setting such as clinical trials, and
when assessed in real-life situations during mass immuniza-
tion campaigns. As expected, the incidence of AEFI was much
higher in clinical trials than in mass campaign studies with
a decrease of more than 99% AEFI detection for all AEFIs
from different phases of clinical trials to immunization cam-
paigns. From this study, it was clear that more than 99% of
overall, local and systemic AEFI detected in clinical trials
could be attributed to the surveillance system put in place
which is not the same during mass campaigns. Due to the
rigorous surveillance system used during clinical trial studies
Table 6. Type and etiology of serious MenAfrivacTM AEFIs in clinical trials.
Study
Duration of
surveillance
in days
Number of
vaccine doses
administered
Type of AEFI
(symptom/sign or
preferred term)
Delay between
vaccination and
AEFI occurrence SOCwhere indicated
Causality
relationship
with the
vaccine
Number
of cases Outcome
Kshirsagar200713 365
(one year)
24 Toothache 6 days Not indicated Unrelated 1 Not indicated
Sow 2011(A)
primary
vaccination26
730 (Two
years)
201 Note indicated Not indicated Infections an
infestations
Unrelated 1 Recovered
Acute
Gastroenteritis
Not indicated Infections an
infestations
Unrelated 1 Death
Protein energy
malnutrition
Not indicated Metabolism and
nutritional disorder
Unrelated 1 Death
Sow 2011(A)
Booster14
730 (Two
years)
192 Injury Not indicated Injury, poisoning
and procedural
complications
Unrelated 1 Death
Note indicates Note indicated Vascular disorders 1 Recovered
Sow 2011(B)14 365 604 Injury and poisoning
and procedural
complications
Unrelated 1 Recovered
Pregnancy,
puerperium and
perinatal conditions
Unrelated 1 Recovered
Hirve 201215 365 169 Acute
lymphoblastic
leukemia
23 days Not indicated 1 Remission
(under
chemotherapy)
Chronic tonsillitis More than 28 days
after
Not indicated Unrelated 1 Recovered
Total 10
aAEFI: Acute Events Following Immunization; b SOC: System Organ Class
(A): study A in the article; (B) study B in the article.
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for AE detection and reporting, there exist high chances of
detecting and reporting more events encountered as opposed
to mass campaigns where the surveillance system for AE
detection and reporting is not consistent or systematic
although a greater population is being served. More of the
AEFI reported during trial studies would have been expected
to be reported in mass campaign studies plus additional rare
and/or new AEs which could not be detected during trials due
to its limited sample size, but the reverse was true from our
findings. More so, 5 out of 40 serious AEFIs investigated in
immunization campaign studies were probably related to the
vaccine whereas none of the serious AEFIs reported in clinical
trials studies was related to the vaccine. Based on this, it can
be deduced that more vaccine-related serious AEs could be
detected in mass campaigns provided the surveillance system
is strengthened to detect more, rare and new AEFI.
Considering the fact that the objectives of clinical trials are
completely different from those of mass immunization cam-
paigns, the former assessing the safety and reactogenicity of
a new product with primary endpoints dependent on the
phase of the trial while the latter being to protect a whole
population from a disease, it is not expected to have equiva-
lent IR of AEFIs. Owing to the fact that, the safety of a vaccine
cannot be ascertained by clinical trials only as a result of its
limited sample size which consequently hinders detection of
significant rare AEFIs, it is highly desirable that a good sur-
veillance system is put in place when a new product is dis-
tributed on a large scale. New serious probably vaccine-related
AEFIs observed during mass immunization campaigns eluci-
dates the importance and necessity of putting in place an
efficient safety monitoring system during such enterprises.
The scope of this review was limited in that, it does not reveal
Table 7. Types and causes of serious AEFIs following administration of MenAfrivacTM in vaccination campaigns.
Study
Duration of
surveillance
in days
Number of
vaccine
doses
administered Type of AEFI (symptom/sign or diagnosis)
Delay between
vaccination and
AEFI occurrence SOC
Causality
relationship
with the
vaccine
Number
of cases Outcome
Maman 201217 42 356ʹ532 Severe malaria (13 were reported to have
fever, 8 convulsions,8 gastrointestinal
disorders and all 14 have positive malaria
smear)
Not indicated Not
indicated
None was
related
(Coincidence)
14 Not clear
Vomiting, diarrhea, hypothermia (35°C),
convulsion and coma
1 day Not
indicated
Not
conducted
1 The child
died two
hours after
admission
Allergic reaction: rash and intense pruritus,
bronchospasm and erythematous and
edematous plaques on all the body
30 minutes Not
indicated
Probably
related to
the vaccine
1 Not clear
Ouandaogo201218 42 11ʹ466ʹ950 Exanthematouspustulosis Not indicated Not
indicated
Probably
related to
the vaccine
1 Not clear
Angioedema Not indicated Not
indicated
Probably
related to
the vaccine
1 Not clear
Bronchospasm Not indicated Not
indicated
Probably
related to
the vaccine
1 Not clear
Vomiting Not indicated Not
indicated
Probably
related to
the vaccine
1 Not clear
Not indicated Not indicated Not
indicated
Coincidence 17 Not clear
Not indicated Not indicated Not
indicated
Unclassified 4 Not clear
Steffen: 201425 5 999 0
Ateudjieu 2016 42 2ʹ093ʹ381 Hypersensitivity Not indicated Not
indicated
Probably
related to
the vaccine
1 Treated
Anaphylacticshock Not indicated Not
indicated
Probably
related to
the vaccine
3 Treated
Meningities Not indicated Not
indicated
Coincidence 6 Treated
Severe
malaria
Not indicated Not
indicated
Coincidence 2 Treated
Septicemia Not indicated Not
indicated
Coincidence 2 Treated
Febrileenteritis, Not indicated Not
indicated
Coincidence 2 Treated
Abdominal trauma Not indicated Not
indicated
Coincidence 1 Treated
Systemicsalmonellosis Not indicated Not
indicated
Coincidence 1 Treated
Total
aAEFI: Acute Events Following Immunization; bSOC: System Organ Class; cC: degree celcius.
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the number of such events that were missed during cam-
paigns. There are certainly many since the IR of serious
AEFI was more than 99% lower in mass campaigns than in
clinical trials. This observation is therefore worrying.
The magnitude of this difference can be explained by
several reasons which can be categorized into two groups;
firstly due to methodological differences and secondly due to
the surveillance systems put in place. For methodological
differences, the duration of observation may have played
a role. Indeed, the surveillance period in clinical trials was
shorter than in mass campaigns. This might have led to
higher overall IR since AEFIs are usually observed in the
Table 8. Incidence rate difference of types AEFI between clinical trials and immunization campaigns.
Type of
AEFI
Incidence rate in clinical trial (number
of AEFI per 100ʹ000 doses
administered per person week)
Incidence rate immunization campaigns
(number of AEFI per 100ʹ000 doses
administered per week)
Incidence rate difference (number of
AEFI per 100ʹ000 doses administered per
week) [95% Conf. Interval]
Attributable Fraction
[95% Conf. Interval]
Pain at the
injection
site
5,119.26 0.36 5,118.90 [5,118.86–5,118.94] 99.99
[0.999928–0.9999311]
Induration:
redness
injection
site
2,126.46 0.02 2,126.44 [1,226.40–1,226.44] 100.00
[0.9999896–0.9999901]
Swelling
injection
site
157.52 0.05 157.46 [157.44–157.48] 99.97
[0.9996183–0.9997453]
Abscess 0.00 0.04 −0.029 [−0.08–0.03] 100.00
Total local
reaction
11,498.65 0.73 11,497.92 [11,497.91–11,497.93] 99.99
[0.9999361–0.9999378]
Fever 2,441.49 1.87 2,439.62 [2,439.61–2,439.63] 99.92
[0.9991781–0.9992864]
Headache 3,622.86 0.66 3,622.20 [3,622.19–3,622.21] 99.98
[0.999811–0.9998238]
Convulsion 0.00 0.06 −0.07 [−0.08, −0.06] 100.00
Cough 0.00 0.18 −0.18 [−0.19, −0.17] 100.00
Running
nose
0.00 0.22 0.–0.22 [−0.23–0.20] 100.00
Irritability 315.30 0.01 315.02 [314.94–315.10] 100.00
[0.9999872–0.9999884]
Asthenia 866.34 0.07 866.27 [866.25–866.29] 99.99
[0.9999316–0.9999382]
Pruritus 0.00 0.17 −0.29 [−0.30–0.28] 100.00
Dizziness or
Sudden
fainting
0.00 0.15 −0.15 [−0.16–0.14] 100.00
Myalgia 236.27 0.18 236.10 [236.09–236.10] 99.94
[0.9992096–0.9994838]
Arthralgia 236.27 0.05 236.23 [236.22–236.24] 99.98
[0.9998028–0.9998493]
Other 78.76 0.08 78.66 [78.65–78.67] 99.38
[0.9862361–0.9971749]
Total
systemic
17,247.97 4.7 17,243.20 [17,241.80–17,245.90] 99.98 [0
.9998454–0.99985]
Ag: At least one study had the number of aggregated in a syndrome.
Table 9. Risks of bias for included studies.
Study
Is there a risk of selection
bias?
Is there a risk of
detection bias?
Is there attrition
bias?
Is there a risk of
reporting bias?
Is there a risk of bias in assessing the etiology
of serious AEFI
Kshirsagar
200713
Unclear1 No4 Unclear6 Unclear8 Unclear9
Sow 20111,14
(A)
Unclear1 No4 Unclear6 Unclear8 Unclear9
Sow 20112,14
(B)
Unclear1 No4 Unclear6 Unclear8 Unclear9
Hirve: 201215 Unclear1 No4 Unclear6 Unclear8 Unclear9
Maman201217 No2 Yes5 Unclear6 Unclear8 Unclear9
Ouandaogo
201218
Yes2 Yes5 Unclear6 Unclear8 Unclear9
Steffen 201425 Yes3 No5 No7 Unclear8 Unclear9
Across studies Yes10 Yes10 Yes10 Yes10 Yes10
1: procedure of participant selection and enrolment not detailed; 2: all eligible people in covered health districts were targeted by the vaccination campaign and AEFI
surveillance; 3: study villages were selected by the Benin Ministry of Health; 4: the detection and reporting processed of AEFI were standardized; 5: Access to AEFI
surveillance expected to differ among persons vaccinated; 6: the number of participants followed up till the end of surveillance period was not indicated; 7: all
participants were followed up till the end of the five days surveillance period; 8: information about the supervision or the monitoring of reporting is not presented.
9: Processes of serious AEFI causality assessment were not presented; 10: the selection and follow up of participants, the AEFIs detection, reporting, and
investigation process differed from one study to others.
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first or second week post-vaccination and therefore, result-
ing to have a much higher numerator. Differing vaccine
safety monitoring procedures, surveillance periods as well
as AEFI reporting and analysis has been identified to con-
tribute in reducing accurate scientific information on vac-
cine safety.27 Also, another reason which can explain these
large differences in IR of AEFI between clinical trials and
mass campaigns can be due to the fact that clinical trial
participants are probably much more aware of AEs than
people who are routinely vaccinated or vaccinated in the
community with an existing vaccine. To maximize scientific
progress on immunization safety, there is essential need for
standardization of AEFI surveillance period in clinical trials
and mass campaigns after registration. The second reason
for this huge IRd can be linked to the poor performance of
the surveillance systems put in place during mass campaigns
to capture AEFIs. There exist many challenges which has
largely been described in previous studies.28 Under-detection
and under-reporting of AEFIs in mass campaigns are well
known and can be rooted in that the activity is not focused
on safety assessment. In clinical trials, the detection, report-
ing, and investigation of AEFIs are part of the TOR (Terms
of Reference) of a well trained, monitored, supervised and
audited research team. Meanwhile, in mass vaccination cam-
paigns, there is limited number of trained health personnel
to carryout supervision of AEFI surveillance, detect, report
and investigate cases of AEFI. Drawing from experiences in
Cameroon, one focal point per health district is designated
and trained for AEFI surveillance supervision and one focal
point per health facility is designated and trained in case
detection, reporting, and investigation of AEFIs. From this
perspective, one person to supervise surveillance in a whole
district and one in a big hospital is clearly not sufficient.
Definitely, within a hospital where many serious cases are
treated in different wards at different times of the day and
night, this poses difficulty in detecting AEFIs that can result
in an SAE. Moreover, consultation registers are mostly not
standardized and do not allow the detection of cases of AEFI
after the consultation because these registers do not include
variables on vaccination history. Thus, cases of AEFIs con-
sulted in the absence of a focal point have very little prob-
ability of being detected. Also, training of supervisors and
surveillance focal points are often carried out in cascade and
integrated with training of other campaign activities due to
inadequate or lack of resources. Added to these, the training
duration is often very short and decreases drastically when
applied from the central to operational level. Consequently,
competence of trainers’ decreases as one trainee cannot
deliver better training than that received in a shorter time.
Improvements can, however, be made which can include: i)
revising the patient registration system to include a variable
for active case detection, ii) ensuring effective and refresher
training to enable them to implement minimum AEFIs
monitoring activities at the operational level, iii) sensitizing
and emphasizing that chiefs of health facilities include the
detection and reporting of AEFI in the TOR of all health
personnel involved in care and more importantly in hospi-
tals, iv) to use efficient interventions such as continuous
supervision and SMS messages to remind health staff of
their surveillance duty.22
Poor performance of AEFI surveillance during mass cam-
paigns is worrying in terms of vaccine safety. This is because i)
local AEFIs such as abscesses, for example, that may be a key
indicator of program error (such as compliance with vaccine
storage, transportation, and administration procedures) are
missed ii) preventable severe local AEFIs are missed which can
likely draw public attention by spreading rumors which might
resort in vaccination refusals by the population, iii) serious
AEFIs are missed thereby compromising causality assessment
and appropriate response possibilities.
To understand whether such differences of AEFIs reporting
between clinical trials and mass vaccinations were inherent to
MenAfrivacTM or were common to all vaccines, we made
a rough estimate of the magnitude of the difference in IR of
AEFIs between clinical trials and post-registration immuniza-
tion using the new pneumococcal 13-valent conjugate vaccine.
For 5308 doses of the vaccine administered during clinical trials,
5004 AEFIs were reported comprising 1803 local and 3201
systemic.29–32 While in post-registration, 871 vaccine doses
were administered and 550 AEFIs were reported of which 236
were local and 314 systemic.33 IRd per 100 000 doses per week
between clinical trials and post-registration vaccination were
19ʹ089, 5ʹ423, and 13ʹ666 for overall, local, and systemic AEFIs
reported, respectively. Thus, AEFI incidence decreased from
clinical trials to post-registration vaccination studies by 52%,
37%, and 53% for overall, local, and systemic AEFI, respectively.
This relatively low difference can be explained by the fact that in
the post-registration study, AEFImonitoring was more rigorous,
which increased the chance of detecting AEFIs than during
studies conducted during the vaccination campaigns with
MenAfrivacTM. More so, vaccinees were closely monitored for
AEFIs by telephone throughout the monitoring period. Lastly,
the vaccinated population was made up of people of older age
from a European country.
Despite the strength of this study, the study was limited in
the methods of estimating AEFI frequency per 100,000 doses
which is unlikely to be true in clinical trial studies with
limited number of doses administered due to its limited
sample size unlike in mass campaigns.
4. Conclusion/recommendations
This systematic review highlights the magnitude of the differ-
ence between IR of AEFI as evaluated in the controlled setting
of clinical trials and more pragmatic approach of mass vacci-
nation campaigns. IR of AEFIs was more than 99% lower in
vaccinations campaigns than in clinical trials, including
reporting of serious ones. Although safety surveillance is an
integral part of both clinical trials and mass vaccination cam-
paigns, IRs of AEFI are not expected to be equivalent in both
settings due to differences in how AEs are collected. However,
there is need to improve the surveillance system put in place
during mass campaign and post-registration implementation
at both national and international levels. At national levels,
this could include aspects such as standardization of hospital
registries to capture information on vaccination status,
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variables that will enhance case detection in hospitals thereby
allowing better investigation of causality, sufficient number of
trainees and dedicated health staff in health facilities and
hospitals, and adequate supervision, coupled with new tech-
nological methods for reminders such as SMS. For these to be
practically achievable, the following strategies could be put in
place. i) Inclusion of specific indicators in consultation regis-
ters to capture information on vaccination status of partici-
pants during routine and mass immunizations ii) the need to
include surveillance aspects as part of campaign communica-
tion strategy. This will aid in conveying surveillance messages
to the population and informing them to report any AEs post
vaccination at health facilities so as to improve AE reporting
rates during campaigns iii) recruitment and training of spe-
cific human resources to handle key responsibilities such as
active case finding of any AEs within the communities, keen
attention at health facilities to consult and record information
of any participants reporting at health facilities due to events
arising from mass campaigns. This strategy can be very effec-
tive as it eliminates the possibility of every non-trained hos-
pital staff at the out-patient station consulting participants
visiting the hospital due to AEFI in the population iv)
Pasting of AEFI case definitions in consultation rooms v)
Using SMSs and telephone beeps to report AEFI in the com-
munity vi) Pasting posters and distribution of flyers illustrat-
ing signs and symptoms of AEFI in the communities to
improve AEFI knowledge within the population and improve
reporting status during campaigns.
At International levels of low and middle-income countries,
feasible approaches which are sustainable, flexible, affordable
and timely for international collaborative vaccine safety moni-
toring and particularly suitable for a consortium of upper, mid-
dle and low-income countries have been suggested in previous
studies. Some have proposed a two-pronged approach which
consists of an integrated coordinated passive surveillance and
international collaborative epidemiological efforts.34 A study
involving LMIC suggested the development of a global network
of hospital-based sentinel sites for vaccine safety signal verifica-
tion and hypothesis testing.35 This study confirmed the feasibil-
ity and demonstrated the validity and utility of large
collaborative international studies to monitor the safety of new
vaccines introduced in LMICs. Another study has proven that,
an international hospital-based network for the investigation of
rare vaccine adverse events, using common standardized proce-
dures and with high participation of LMICs, is feasible, can
produce reliable results, and has the potential to characterize
differences in risk between vaccine strains.36
5. Material and methods
5.1. Study design
This was a systematic review study in which all studies pub-
lished that reported on adverse events following MenAfrivac™
administration during clinical trials and immunization cam-
paigns were identified. An estimated incidence rate (IR) of
overall, local, systemic, serious and types of reported AEFIs
was compared between clinical trials and immunization cam-
paigns studies using the incidence rate difference (IRd).
5.2. Study settings
This study covered clinical trials or mass campaign studies on
MenAfrivac™ in seven (7) African countries and one (1) Asian
country. Hence, studies from a total of eight countries were
included namely; India, Mali, Gambia, Senegal, Niger,
Burkina Faso, Benin, and Cameroon.
5.3. Study population
The study population comprised individuals vaccinated with
MenAfrivac while enrolled in clinical trials or during vaccina-
tion campaigns. Studies that reported on adverse events fol-
lowing immunization with meningococcal group A conjugate
vaccine were included. These studies reported AEFI from
male and female subjects’ age 1–35 years because these age
groups are usually targeted during clinical trials and vaccina-
tion campaigns with MenAfrivac™.
5.4. Literature search
The following sources were searched from February 15 –
March 17, 2015 and cross-checked in August 29, 2016 to
detect any recently published papers: meningitis vaccine26
project website, Medline (PubMed) and Embase (Ovid). The
search consisted of keywords relating to the disease of interest
combine with other key terms using Boolean operators. The
following terms were therefore used for the literature search:
‘’meningococcal meningitis A’’AND‘’conjugate
vaccine’’AND‘’safety’’ in Medline; and ‘’meningococcus’’ OR
“Neisseria meningitidis group A’’ AND ‘’conjugate vaccine’’
AND ‘’safety’’ in Ovid. The reference lists of all included
primary and review articles were examined to identify cited
articles not captured by electronic searches. The search was
restricted to articles published in English Language. The data-
base was scrutinized by two reviewers and full articles likely to
meet the selection criteria were obtained. The reviewers made
the final inclusion/exclusion decisions according to adherence
to the eligibility criteria.
5.5. Eligibility criteria
Phase 1, 2, 3 clinical trial studies, and mass immunization
campaign studies reporting AEFIs after exposure to
MenAfrivac™ were considered eligible to be included in this
study. The review only included studies/reports published in
English.
5.6. Selection criteria
Inclusion criteria: Reports and studies published in English
during 2001–2016 which reported AEFI with MenAfrivac
were included in this study. Study participants exposed to
MenAfrivac™ were included. The WHO definition of AEFI
was used in this study.1,37
Exclusion criteria: i) unpublished reports, reports not pub-
lished in peer-reviewed scientific journal, ii) publications
reporting AEFIs associated concomitant exposure of partici-
pants to MenAfrivac™ and other vaccines or drugs; iii)
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duplicates (case where more than one publication reports
AEFIs from the same population over the same period); iv)
publications with AEFIs reported in preclinical phase of
MenAfrivac™ development; v) publications for which the full
text was not available; and vi) abstracts of conferences. Also,
studies with participants to whom the vaccine administered
were not done following manufacturer’s dose, administration
or storage procedures were excluded from this study.
The selection process was conducted by two independent
reviewers using a two-step process: the first step included
assessing the title and abstract of articles and reports, and
the second step involved assessing the full text using the
selection criteria. All disagreements arising were resolved
by consulting the full text of articles.
5.7. Data extraction
This study adapted a data extraction grid that was used in
a previous study.11 Data were extracted and compiled in an
excel table by a reviewer. A second reviewer cross-checked all
extracted data one after another while comparing with data in
the excel table in order to fill data extraction forms and full
texts of articles. Wherever discrepancies were observed, cor-
rections were made from the full-text article. From each
article, the following characteristics were extracted: study
characteristics which included the study design, year of pub-
lication, study country, health-care setting, type of resource
available, source of the report, and name of the first author;
characteristic of the study population such as size, age group,
inclusion criteria, exclusion criteria and number of pregnan-
cies exposed; phase of the vaccine development (phase 1, 2, 3,
4 clinical trials, mass immunization campaign, routine EPI);
characteristics of the vaccination such as antigen, dose,
administration procedure, other vaccine or drugs concomi-
tantly administered and first or second dose; characteristics of
the AEFI surveillance system including case definition of
AEFI, case definition of serious AEFI, type of surveillance
(active, passive stimulated or not), surveillance duration,
type of AEFI investigated); characteristics of reported AEFIs,
namely, total number, number of serious, local and systemic
reaction, number of AEFIs per age group, number of AEFI
per type, number of cluster AEFIs, number and type of AEFIs
among pregnant women, number of serious AEFIs investi-
gated, number of vaccine product-related reaction, number of
vaccine quality defect-related reaction, number of immuniza-
tion error-related reaction (formerly “program error”), num-
ber of immunization anxiety-related reaction, number of
coincidental events].
5.8. Outcomes
The primary outcome of this study is the incidence rate
difference (IRd) of overall AEFIs between clinical trials and
mass campaign studies. Secondary outcomes included the IRd
comparing local, systemic, serious and types of AEFIs between
clinical trials and mass campaign studies.
5.9. Quality assessment
This study assessed the procedures of participants’ selection, the
adopted case definitions of AEFIs, procedures of AEFIs detection,
reporting and investigation to ensure the methodological quality
of studies. The quality assessment was performed by two indepen-
dent reviewers who resolved any arising discrepancy through
discussions.
5.10. Data analysis
IR (incidence rate) per 100ʹ000 doses administered per week of
overall, local, systemic, and serious and types of AEFIs in clinical
trials and mass campaigns were estimated. The sum of AEFI cases
reportedwas defined as the numerator of the incidence rate and its
denominator was defined as the sum of persons exposed to the
vaccine multiplied by the duration of follow up. AEFI IRs in
clinical trials were compared to that of post-registration phases
by estimating the IRd at 95% confidence interval and the attribu-
table fraction of AEFI IR in clinical trials and mass campaigns.
Datawere entered inMicrosoft excel 2010 analyzed using the same
software and STATA version 10 (Texas, 2009).
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